Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
M.D. Anderson Cancer Center
Genentech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nammi Therapeutics Inc
Jazz Pharmaceuticals
Pfizer
IDEAYA Biosciences
Zumutor Biologics Inc.
China Medical University, China
National Cancer Institute (NCI)
SystImmune Inc.
Tel-Aviv Sourasky Medical Center
Alentis Therapeutics AG
Exelixis
Mayo Clinic
Neonc Technologies, Inc.
Myeloid Therapeutics
Daiichi Sankyo
Jonsson Comprehensive Cancer Center
Genentech, Inc.
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Hoffmann-La Roche
Innate Pharma
Dren Bio
Mayo Clinic
Inhibrx Biosciences, Inc
Tanabe Pharma America, Inc.
RenJi Hospital
Mayo Clinic
Tampere University Hospital
Massive Bio, Inc.
ITM Oncologics GmbH
Incyte Corporation
University of Erlangen-Nürnberg Medical School
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Xencor, Inc.
NuCana plc
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Affiliated Hospital of Jiangnan University